[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"implant-site-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:implant-site-infection":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100418616","phase-3-local-antibiotics-for-breast-implants-100418616",false,"NCT04731025","Local Antibiotics for Breast Implants","Prophylactic Treatment of Breast Implants With a Solution of Gentamicin, Vancomycin and Cefazolin Antibiotics for Women Undergoing Breast Reconstructive Surgery: a Randomized Controlled Trial (The BREAST-AB Trial)","BREAST-AB","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Biologically female\n* Signed informed consent\n* Scheduled for breast reconstruction with implants or expanders including:\n\n  1. Immediate or delayed reconstructions\n  2. Bilateral or unilateral reconstructions\n  3. With or without simultaneous flap reconstruction\n\nExclusion Criteria:\n\n* Pregnancy\n* Breast feeding\n* Known allergy towards Vancomycin, Gentamicin and Cefazolin\n* Known anaphylactic reaction towards other beta-lactam antibiotics or aminoglycosides\n* Known allergy towards neomycin\n* Known impaired renal function with GFR \\\u003C 60 mL\u002Fmin\n* Participation in investigational drug trials and projects concerning disinfecting agents in the breast implant cavity\n* Myasthenia Gravis",true,"FEMALE","18 Years",{"count":21,"type":22},1003,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","The BREAST-AB Trial is a multi-center, randomized, double blind, placebo-controlled trial investigating the efficacy of local application of gentamicin, vancomycin and cefazolin in decreasing all-cause implant explantation after breast reconstruction.",[28,29,30,31,32,33,34],"Implant Complication","Implant Infection","Implant Site Infection","Implant Capsular Contracture","Implant Site Pocket Infection","Implant Expulsion","Antibiotic Side Effect","RECRUITING","2026-02-09",{"date":38,"type":39},"2026-02-12","ACTUAL",{"date":41,"type":39},"2021-01-27",{"date":43,"type":22},"2027-08",{"name":45,"class":46},"Mikkel Herly","OTHER",8,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":54,"minAge":19,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100555730","characterizing-the-inflammation-around-dental-implants-bacterial-infection-hypersensitivity-or-both-100555730","NCT06515886","Characterizing the Inflammation Around Dental Implants: Bacterial Infection, Hypersensitivity or Both?","Inclusion Criteria:\n\n* Received at least one functional implant (implant restored with a prothesis);\n* Did not receive peri-implant mucositis and peri-implantitis treatment in the past three months.\n\nExclusion criteria:\n\n* Dental records with incomplete information;\n* Individuals with a weak immune system or chronic disease such as diabetes, heart, lung or kidney disease;\n* Pregnant women;\n* Individuals undergoing orthodontic therapy and those who have oral piercing.\n* History of diseases that modify or suppress the immune and inflammatory response, including rheumatoid arthritis, diabetes, lupus, and inflammatory bowel disease and metastatic cancer;\n* Taking medications that cause antiresorptive osteonecrosis of the jaw (including any dose of intravenous bisphosphonates, oral bisphosphonate intake for more than three years, receptor activator of nuclear factor kappa-B ligand inhibitors, or antiangiogenic medications);\n* Taking medications known to induce gingival hyperplasia including anticonvulsants, immunosuppressants, or calcium channel blockers;\n* Taking steroid medications, systemic or local antibiotics in the last three months (as this may affect the interleukins activity);\n* Received radiation therapy to the head and neck or chemotherapy;\n* Received treatment to manage an inflamed implant, including management of peri-implantitis and peri-implant mucositis in the last three months.","ALL",{"count":56,"type":22},40,"OBSERVATIONAL","The use of titanium dental implants has become a common modern treatment to restore teeth. Although the success rate of dental implants is high, inflammation around the dental implant still occurs. The current study will investigate if the inflammation around the implant is due to bacterial infection, hypersensitivity or both.",[60,28,30,61],"Dental Implant Failed","Implant Site Reaction",[63,64,65,66,67,68],"Dental implant","Peri-implant inflammation","Inflammatory mediators","Bacterial infection","Hypersensitivity","peri-implantitis","2024-07-19",{"date":71,"type":39},"2024-07-23",{"date":73,"type":39},"2022-09-22",{"date":75,"type":22},"2025-12-01",{"name":77,"class":46},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre",1]